StockData
Baxter International Inc logo

Baxter International Inc (BAX) KPIs and segments

BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/306% above fair value
$26.16+0.40 (+1.55%)

Close on Nov 18, 2026Market cap $13.53BP/E –Yield 1.99%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Baxter International · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Baxter International: 49 chỉ số vận hành, trong đó có Organic / Operational Sales Growth, Medical Products & Therapies (MPT) và Healthcare Systems & Technologies (HST), lấy từ 146 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Medical Products & Therapies($M)5
2,1022,0761,2851,3881,9771,9451,2621,3141,3421,3221,2291,320
Infusion Therapies & Platforms($M)
1,7601,7451,6711,649
International($M)
1,1481,1255946681,0691,034533596580593556598
Infusion Therapies and Technologies($M)
9811,0601,0231,0249941,0221,0701,0459661,042
United States($M)
954951691134908911729718762729673722
Advanced Surgery($M)
342331304328306296268292272277263278
Healthcare Systems & Technologies($M)4
806801705827773767704784752748667795
United States($M)
601587513586577562518574557550473561
Care and Connectivity Solutions($M)
498502435537473474427504456452402493
Front Line Care($M)
308299270290300293277280296296265302
International($M)
205214192241196205186210195198194234
Pharmaceuticals($M)4
621668632612581643588602578597
International($M)
441478455425386429410405387388
Drug Compounding($M)
320316299280246260267261250237
Injectables and Anesthesia($M)
301352333332335383321341328360
United States($M)
180190177187195214178197191209
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
United States($M)
1,5951,5951,4351,5521,5441,5361,4901,5101,5001,4921,3481,502
International($M)
1,3811,3651,2661,4221,2911,2741,1351,2431,1991,2021,1421,224
Rest of world($M)
1,024936930838894852855835866
Emerging markets($M)
398355344297349347347307358
Medical Products & Therapies($M)
439400186-288411444244217268238227266
Healthcare Systems & Technologies($M)
13916366411221569314513612067156
Pharmaceuticals($M)
4639566463102587578117
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Medical Products & Therapies($M)
780745504524751788568583608588561
Healthcare Systems & Technologies($M)
361399315367359392348414384368321
Pharmaceuticals($M)
163165182184185228180195196
Remaining performance obligations (RPO)($M)
7,5807,9108,8709,89010,08010,1902,7504,1605,780
Organic / Operational Sales Growth — Continuing Operations(%)5
5.0%5.0%-1.0%3.0%2.0%1.0%5.0%4.0%4.0%3.0%3.0%
U.S. Organic / Operational Sales Growth(%)
5.0%4.0%-4.0%-1.0%-1.0%-1.0%7.0%
International Organic / Operational Sales Growth(%)
6.0%5.0%3.0%8.0%5.0%3.0%3.0%
Reported GAAP Net Sales Growth — Continuing Operations(%)
5.0%5.0%3.0%8.0%5.0%4.0%5.0%4.0%3.0%2.0%4.0%
Foreign Exchange (FX) Impact on Sales Growth(%)
-1.0%-1.0%-3.0%-2.0%-1.0%0.0%2.0%0.0%1.0%1.0%-1.0%
Kidney Care MSA Impact on Reported Sales Growth(%)
1.0%1.0%-1.0%-3.0%-3.0%-4.0%-3.0%
Medical Products & Therapies (MPT) — Organic / Operational Sales Growth(%)4
6.0%5.0%-1.0%3.0%2.0%0.0%5.0%7.0%5.0%6.0%4.0%
Infusion Therapies & Platforms (ITP) — Organic / Operational Growth(%)2
4.0%4.0%-3.0%1.0%0.0%-1.0%5.0%
ITP — Reported Sales Growth(%)
5.0%6.0%2.0%3.0%0.0%-1.0%2.0%
ITP — Foreign Exchange (FX) Impact(%)
-1.0%-2.0%-5.0%-2.0%-1.0%-1.0%2.0%
Advanced Surgery — Organic / Operational Sales Growth(%)2
12.0%12.0%10.0%11.0%11.0%5.0%4.0%7.0%4.0%8.0%6.0%
Advanced Surgery — Reported Sales Growth(%)
12.0%12.0%13.0%12.0%13.0%7.0%2.0%7.0%2.0%7.0%7.0%
Advanced Surgery — Foreign Exchange (FX) Impact(%)
0.0%0.0%-3.0%-1.0%-2.0%-2.0%2.0%0.0%2.0%1.0%-1.0%
Legacy Infusion Therapies & Technologies — Operational Growth (Through Q1 2026)(%)
-5.0%1.0%-4.0%-1.0%6.0%7.0%5.0%6.0%4.0%
Legacy Pharmaceuticals Segment — Operational Growth (Through Q1 2026)(%)2
1.0%2.0%7.0%1.0%3.0%1.0%11.0%11.0%7.0%
Healthcare Systems & Technologies (HST) — Organic / Operational Sales Growth(%)2
4.0%4.0%-2.0%4.0%2.0%2.0%6.0%1.0%1.0%-9.0%7.0%
Care & Connectivity Solutions (CCS) — Organic / Operational Growth(%)2
5.0%5.0%0.0%4.0%3.0%4.0%7.0%3.0%4.0%-7.0%11.0%
CCS — Reported Sales Growth(%)
5.0%6.0%2.0%7.0%4.0%5.0%6.0%3.0%4.0%-6.0%12.0%
CCS — Foreign Exchange (FX) Impact(%)
0.0%-1.0%-2.0%-3.0%-1.0%-1.0%1.0%0.0%0.0%-1.0%-1.0%
Front Line Care (FLC) — Organic / Operational Growth(%)2
3.0%2.0%-4.0%3.0%1.0%-1.0%5.0%-2.0%-4.0%-12.0%2.0%
FLC — Reported Sales Growth(%)
3.0%2.0%-3.0%4.0%1.0%-1.0%5.0%-2.0%-4.0%-12.0%3.0%
FLC — Foreign Exchange (FX) Impact(%)
0.0%0.0%-1.0%-1.0%0.0%0.0%0.0%0.0%0.0%0.0%-1.0%
RPO Expected Revenue Recognition — Next Calendar Year (Year + 1 Share)(%)3
25.0%25.0%20.0%25.0%20.0%20.0%20.0%25.0%25.0%50.0%
RPO Expected Recognition — Remainder of Current Year (Q1–Q3 Filings)(%)
10.0%10.0%25.0%5.0%10.0%15.0%25.0%
RPO Expected Recognition — Year + 2 Share(%)
20.0%20.0%15.0%25.0%20.0%20.0%15.0%20.0%20.0%25.0%
RPO Expected Recognition — Year + 3 Share(%)
20.0%20.0%15.0%15.0%15.0%15.0%15.0%20.0%20.0%15.0%
Medical Equipment Lease Revenue — Infusion Pumps & Smart Beds($M)4
1029310093919510610011589114102
Operating Lease Revenue($M)
88859086868791921028210495
Variable Usage-Based Lease Revenue($M)
7777587610486
Sales-Type Lease Revenue($M)
713000823321
Net Investment in Sales-Type Equipment Leases($M)
292430303338473736706950
Customer Contract Assets — Placed Equipment & Software($M)5
111122136147138129132133145153156165
Bundled Equipment & Consumable Medical Products Contract Assets($M)
88921001109987898795102108116
Medical Device Software Arrangements Contract Assets($M)
232731343436394446454145
Contract Manufacturing Services Contract Assets($M)
035356424674
Current Contract Assets($M)
626470716555545154535353
Non-Current Contract Assets($M)
495866767374788291100103112
Installation & Service Contract Liabilities (Deferred Service Backlog)($M)3
161166182177159178175171160156169169
New Installation & Service Revenue Deferrals (Bookings)($M)
1461191872171301301281711831079377
Installation & Service Contract Revenue Recognized($M)
1521351822071441261241661761229177
Revenue Recognized from Opening Contract Liability Balance($M)
3544462632233492130436
FDA 510(k) Premarket Device Clearances1
111130312050
FDA Premarket Approvals (PMA & Supplements)
210224124223
FDA Medical Device Recall Events (openFDA)1
122318101625421511273
FDA Device Enforcement Reports
12231993211401615224
FDA MAUDE Medical Device Adverse Event Reports — Total3
2,7342,9432,8893,3733,0473,5534,2824,7674,1713,9883,6594,037
Infusion Therapies & Platforms (ITP) — U.S. Net Sales($M)1
768769711728740753786779794792728
ITP — U.S. Reported Sales Growth(%)
4.0%2.0%-10.0%-7.0%-7.0%-5.0%8.0%
Infusion Therapies & Platforms (ITP) — International Net Sales($M)1
9929769051,007931896804898881877832
ITP — International Reported Sales Growth(%)
7.0%9.0%13.0%12.0%6.0%2.0%-3.0%
Advanced Surgery — U.S. Net Sales($M)1
186182165177168158145157149150147149
Advanced Surgery — U.S. Reported Sales Growth(%)
11.0%15.0%14.0%13.0%13.0%5.0%-1.0%7.0%0.0%2.0%2.0%
Advanced Surgery — International Net Sales($M)1
156149139151138138123135123127116129
Advanced Surgery — International Reported Sales Growth(%)
13.0%8.0%13.0%12.0%12.0%9.0%6.0%6.0%4.0%14.0%13.0%
Care & Connectivity Solutions (CCS) — U.S. Net Sales($M)1
362361315367348341316366335332278337
CCS — U.S. Reported Sales Growth(%)
4.0%6.0%0.0%0.0%4.0%3.0%14.0%6.0%7.0%-7.0%11.0%
Care & Connectivity Solutions (CCS) — International Net Sales($M)1
136141120170125133111138121120124156
CCS — International Reported Sales Growth(%)
9.0%6.0%8.0%23.0%3.0%11.0%-10.0%-4.0%-4.0%-5.0%13.0%
Front Line Care (FLC) — U.S. Net Sales($M)1
239226198219229221202208222218195224
FLC — U.S. Reported Sales Growth(%)
4.0%2.0%-2.0%5.0%3.0%1.0%4.0%-5.0%-4.0%-12.0%0.0%
Front Line Care (FLC) — International Net Sales($M)1
697372717172757274787078
FLC — International Reported Sales Growth(%)
-3.0%1.0%-4.0%-1.0%-4.0%-8.0%7.0%10.0%-3.0%-14.0%13.0%
Kidney Care MSA & Other Unallocated Revenue($M)3
68837684859863000018
Kidney Care MSA & Other — U.S. Net Sales($M)
40574661596341000014
Kidney Care MSA & Other — International Net Sales($M)
2826302326352200004
Other / Kidney Care MSA Operating Income (Loss)($M)
10675566-12-15-4-1
Legacy Infusion Therapies & Technologies — U.S. Net Sales (Through Q1 2026)($M)3
526543555554584561613579526573
Medical Products & Therapies (MPT) — Segment Operating Margin(%)2
20.9%19.3%14.5%15.4%20.5%18.1%19.3%
Healthcare Systems & Technologies (HST) — Segment Operating Margin(%)
17.2%20.3%9.4%15.2%13.5%15.4%13.2%
Legacy Pharmaceuticals Segment — Operating Margin (Through Q1 2026)(%)
7.4%5.8%8.9%10.5%10.8%9.9%7.4%14.4%8.0%
Adjusted Operating Income — Continuing Operations (Non-GAAP)($M)5
432421297352423423392391522515630
Adjusted Diluted EPS — Continuing Operations (Non-GAAP)($)
0.580.560.360.440.690.590.550.490.680.650.88
Full-Year Adjusted Diluted EPS Guidance — Low($)
2.051.951.851.85
Full-Year Adjusted Diluted EPS Guidance — High($)
2.152.152.052.05
Free Cash Flow — Continuing Operations (Non-GAAP)($M)
44818176-2210
Unallocated Corporate Costs($M)
1561481592411151831391611821702100
Hurricane Helene North Cove Plant Remediation & Recovery Costs($M)4
3331081798852500
Product-Related & Infusion Pump Field Corrective Action Charges (Net)($M)
00-125232236123000
European Medical Devices Regulation (EU MDR) Compliance Costs($M)
3446555899710
Kidney Care (Vantive) & Spin-Off Separation Costs($M)
22211181314130000102
Business Transformation Program Costs($M)
20231100
Business Optimization & Restructuring Special Charges($M)3
61768783817451131892226
Restructuring — Employee Severance & Termination Costs($M)
2105860185266912314-3
Restructuring — Asset Impairments & Write-Offs($M)
330169518857
Restructuring — Contract Termination & Exit Costs($M)
82211042313-3
Inventories — Finished Goods($M)3
1,3111,2781,3591,3271,5761,4941,3101,2701,3151,9271,9221,154
Inventories — Raw Materials($M)
560555567536573587550510532750750530
Inventories — Work in Process($M)
429426390369311303310266256308316234
Allowance for Credit Losses on Accounts Receivable($M)
55566763697166716512312162
Property, Plant & Equipment — Gross Carrying Value($M)3
8,2048,1778,0998,0547,7507,6887,4317,6487,60510,77411,1977,650
Accumulated Depreciation & Amortization on PP&E($M)
5,3315,2645,1865,1444,9384,8864,7144,7784,7726,4606,8274,779
Intangible Asset Amortization Expense($M)
145145146145147151155154159154158156
Operating Lease Right-of-Use Assets Obtained($M)
12320222751023151611
Discontinued Operations (Kidney Care / Vantive & BioPharma Solutions) — Operating Cash Flow($M)
0-120-1200-9445-9315296116
U.S. Federal Contract Action Obligations — Baxter Healthcare (VA, DoD & HHS)($M)
14.50.560.230.625.54-0.010.221.800.5810.30.361.50
U.S. General Medical & Surgical Hospitals Revenue (Census QSS)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Total U.S. MedTech Industry — FDA 510(k) Clearances1
856923756806797886736856767793713877
Total U.S. MedTech Industry — FDA PMA Approvals
565608567525585588524683538550459656
Consolidated Net Sales (Continuing Operations)($M)6
2,9762,9602,7012,9742,8352,8102,6252,7532,6992,6942,4902,729
Gross Profit($M)
9941,0328915779509918619591,0331,0319611,100
Selling, General & Administrative Expenses($M)
730735728761708718703761754723729683
Research & Development Expenses($M)
125129139126118134140211129130120127
Operating Income (Loss)($M)
22521766-72917219158-435155179115304
Income (Loss) from Continuing Operations($M)
298135-17-1,035-5112264-48861956219
Net Income (Loss) Attributable to Baxter Stockholders($M)
294126-15-1,128-4691126-512140-31437245
Operating Cash Flow($M)2
558285213584237217-193488253115163531
Depreciation & Amortization($M)
239239237240237257247245254227271264
Stock-Based Compensation($M)
303310373535103938201725
Total Assets($M)6
19,41419,79119,84620,05521,06721,04621,30425,78226,67626,31227,78828,276
Cash & Cash Equivalents($M)
1,9752,1502,0171,9661,7261,6862,2941,7641,4201,5742,8263,078
Accounts Receivable, Net($M)
1,7831,8561,6981,8611,7771,7731,6461,6791,7292,6392,5211,719
Total Inventories, Net($M)
2,3002,2592,3162,2322,4602,3842,1702,0462,1032,9852,9881,918
Goodwill($M)
4,8714,8864,8994,9295,4005,3955,3385,2755,7836,0016,4305,793
Other Intangible Assets, Net($M)
3,9274,0734,2184,3694,8054,9505,0815,2235,4495,7415,9055,918
Total Liabilities($M)
12,93913,61213,83013,95313,85313,75314,25018,75818,73418,60419,55319,808

62 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Baxter International Inc.'s latest reported fiscal period is Q3 2026 (ended September 30, 2026; Form 8-K Earnings Release & Form 10-Q filed October 29, 2026; FY2025 Form 10-K filed February 12, 2026).
  • Q2 2026 Segment Realignment & Kidney Care Divestiture: Beginning in Q2 2026 (recast via Form 8-K filed July 14, 2026), Baxter folded its former Pharmaceuticals segment (Injectables & Anesthesia and Drug Compounding) into the Infusion Therapies & Platforms (ITP) division of Medical Products & Therapies alongside Advanced Surgery, while Healthcare Systems & Technologies comprises Care & Connectivity Solutions and Front Line Care. All continuing operations exclude the former Kidney Care segment (Vantive), divested to Carlyle on January 31, 2025 (~$3.8B purchase price); ongoing Manufacturing and Supply Agreement (MSA) revenues to Vantive are reported in Other.
  • Commercial Equipment Placement & Leasing Model: Baxter places infusion systems (Spectrum IQ, Novum IQ) and hospital smart beds (Progressa+, Centrella) under ASC 842 operating, variable usage-based, and sales-type leases ($385M lease revenue and $375M gross customer-leased equipment fleet in FY2025) as well as bundled upfront equipment-and-consumable contracts ($110M contract asset at FY2025, collected over 1–7 years) and installation/maintenance service deferrals ($605M new deferrals in FY2025).
  • Subsidiary & Standalone Scope: Baxter files consolidated U.S. GAAP financial statements without standalone parent-only financial statements; all principal operating subsidiaries (including Hill-Rom Services, Inc., Welch Allyn Inc., and Baxter Healthcare Limited in the UK) are 100% wholly owned. Statutory annual workforce pay disclosures of UK operating subsidiary Baxter Healthcare Limited (Co. No. 00461365) are included.
  • Methodology: Every value is directly as published in SEC filings, Baxter Corporate Responsibility Reports, U.S. FDA openFDA, ClinicalTrials.gov, USAspending.gov, UK Government statutory filings, or BLS/Census FRED series. The only derived cells are discrete quarterly splits from cumulative year-to-date disclosures (quarter = YTD minus prior YTD; Q4 = full year minus nine months), displayed in italics with their exact formula.

Không hiện vì thiếu các kỳ gần đây (8)

  • Remaining Performance Obligations Total Dollar Balance ($7.58B at Q3 2026) — Already displayed automatically in the Core XBRL KPI section via us-gaap:RevenueRemainingPerformanceObligation; maturity recognition percentages (Remainder of Year, Year+1, Year+2, Year+3) are tracked in Group 2.
  • Top-Level GAAP Segment Net Sales & Operating Income (Medical Products & Therapies, Healthcare Systems & Technologies, legacy Pharmaceuticals, and consolidated U.S. / International totals) — Already displayed automatically by the Segment XBRL view; granular U.S. vs. International division net sales, Kidney Care MSA revenues, and organic constant-currency growth bridges are tracked in Groups 1 and 4.
  • Global Commercial Reach ('sold in over 100 countries' and 'manufactured in more than 20 countries' in Form 10-K Item 1) — Disclosed only as lower bounds ('over 100', 'more than 20') rather than exact point counts.
  • Patients Supported Worldwide ('approximately 350 million patients annually' / 'more than 350 million patients' in Proxy Statement) — Disclosed only in promotional narrative with bound qualifiers across fewer than two consecutive comparable periods.
  • Full-Year 2026 Organic Sales Growth Guidance in Q4 2025 & Q1 2026 ('approximately flat') — Stated qualitatively without numerical range bounds in Q4 2025 and Q1 2026 prior to numerical range resumption ('2% to 3%' in Q2 2026 and '3% to 4%' in Q3 2026).
  • Care & Connectivity Solutions U.S. Capital Orders Growth (+9% in Q4 2024, 'over 30%' in Q4 2025) — Disclosed intermittently on fourth-quarter earnings calls and as a lower bound ('over 30%') in Q4 2025.
  • North Cove Facility Manufacturing Lines Restarted Post-Hurricane Helene (8 of 10 lines in Q4 2024; final 2 lines in January 2025) — One-time post-hurricane recovery milestone disclosed in Q4 2024 commentary rather than a recurring quarterly series.
  • 2025 Sustainability Report Annual Environmental & Safety Metrics (FY2025) — Hosted on investor.baxter.com behind a Cloudflare Turnstile challenge gate; historical multi-year assured data through FY2024 is presented from open public Corporate Responsibility Reports.

Dữ liệu cập nhật 2026-11-18.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Baxter International

See a number that looks wrong?